Inclusion Criteria:

1. Patient has given written informed consent

2. Patient is 18 years or older

3. Patient has histologically confirmed prostate cancer

4. Patient has a serum prostate-specific antigen (PSA) level at screening >2 ng/mL

5. The prostate size is >30 cubic centimetres (cc), measured by TRUS

6. Patient has had a bone-scan within 12 weeks before inclusion

7. Patient must be able to undergo transrectal examinations

8. Patient has an estimated life expectancy of at least 12 months

Exclusion Criteria:

1. Any previous treatments for prostate cancer

2. Previous trans-urethral resection of the prostate (TURP)

3. Is not considered a candidate for medical castration

4. Use of urethral catheter

5. Is currently treated with a 5-alpha reductase inhibitor

6. Is currently treated with an alpha-adrenoceptor antagonist

7. Treatment with botulinum toxin A (Botox)

8. Require radiotherapy during the trial

9. History of severe untreated asthma, anaphylactic reactions, or severe urticaria
and/or angioedema

10. Hypersensitivity towards any component of the investigational products or excipients

11. Previous history or presence of another malignancy

12. A clinically significant disorder

13. A corrected QT interval over 450 msec

14. Mental incapacity or language barrier precluding adequate understanding or
co-operation

15. Receipt of an investigational drug within the last 28 days proceeding screening

16. Previous participation in any degarelix trial